The phase 1 clinical trial of Krystal Biotech Inc.'s potential inhaled treatment for solid tumors of the lung has seen its first patient dosage.
KB707 is an inhaled treatment for a solid tumor, either locally advanced or metastatic. It has been on the fast-track designation from the U.S. Food and Drug Administration in two separate types of treatment.
"Dosing the first patient in our inhaled KB707 trial is another important milestone for our oncology program and for Krystal," said Krystal Biotech's President of Research and Development, Suma Krishnan.
"Cytokine therapy holds significant potential for the treatment of solid tumors but its utility has been limited by a lack of safe and effective options," said Dr. David Chien, who is SVP of clinical development at the Pittsburgh-based Krystal (Nasdaq: KRYS) in a statement. "Cytokine delivery via inhalation is a first-of-its-kind therapeutic approach made possible by the unique attributes of Krystal's HSV-1 based vector platform."
Krystal reported in February that it had logged the first stream of revenue for the company for the launch of another product, a gene therapy known as Vjyuvek, which treats a rare skin disease called DEB. It had $50.7 million in revenue in 2023.
